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Over the last decade, there has been a great increase in our under-
standing of the genetic basis of colorectal tumour development
(Martin et al, 1999). In particular, there has been recognition of a
distinct pathway of colorectal carcinogenesis, characterized by
sporadic or hereditary defects in DNA repair enzymes, and defined
genetically by microsatellite instability (Ionov et al, 1993;
Peltomaki et al, 1993; Thibodeau et al, 1993; 1998; Herman et al,
1998; Velgl et al, 1998). This new knowledge has thrown into
relief the more typical pathway of colorectal cancer (CRC)
progression, characterized by mutations of p53 and chromosomal
aneuploidy, a phenomenon often referred to as chromosomal
instability (Cianchi et al, 1999). Aneuploidy is detected in 60–90%
of colorectal cancers, and in many (Witzig et al, 1991; Tsuchiya
et al, 1992; Lanza et al, 1998; Pietra et al, 1998; Flyger et al, 1999)
but not all studies (Visscher et al, 1990; Cohn et al, 1997; Tonouchi
et al, 1998) has been associated with worse disease outcome. 
It has been widely assumed that either chromosomal or
microsatellite instability pathways underly colorectal tumour
development. However, a recent study has demonstrated that a
percentage of colorectal carcinomas show neither pattern of
genetic instability, and may represent a potentially distinctive form
of the disease (Georgiades et al, 1999). The authors postulated
that these seemingly genetically stable tumours may have
developed through an as yet uncharacterized unique molecular
pathway. 
In this report, we have classified apparently sporadic colorectal
carcinomas according to the presence or absence of both chromo-
somal and microsatellite instability, and have assessed the clinico-
pathological features of those tumours characterized by both
chromosomal and microsatellite stability. 
MATERIALS AND METHODS 
Patient recruitment and follow-up 
After obtaining informed consent, 43 consecutive individuals under-
going surgical resection of adenocarcinoma of the colon or rectum at
St Vincent’s Hospital, Sydney, were enrolled in this study. Individuals
were excluded where preoperative radio or chemotherapy had been
administered. Patients with inflammatory bowel disease, or with a
known history of familial adenomatous polyposis (FAP) or hereditary
non-polyposis coli (HNPCC) were also excluded from this study, as
were those individuals where the primary tumour was incompletely
resected (R1 or R2) (Hermanek and Sobin, 1998). Fresh representa-
tive tissue samples (500 µg) from all tumours and paired normal
colonic mucosa were used immediately for flow cytometric analysis,
or stored at -70˚C for DNA extraction. 
Histopathological analysis of tumours 
For all tumours, the histopathological type, stage and size of the
tumour were determined independently by a histopathologist within
the Department of Anatomical Pathology, St Vincent’s Hospital.
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The tumour grade, extent of mucin production, tumour growth
pattern, and presence of intraepithelial lymphocytes, were deter-
mined prospectively without knowledge of the mismatch repair
status. Tumours in which less than 10% of cells formed glands were
classified as high-grade (poorly differentiated), while those
containing more than 50% extracellular mucin were classified as
mucinous (Jass and Sobin, 1989). The tumour growth pattern was
interpreted as either infiltrative or expansile, as per previously
published criteria (Jass et al, 1996). Intraepithelial lymphocytes
were identified by light microscopy on haematoxylin and eosin
sections as cells with the morphology of lymphocytes, seen wholly
within tumour epithelium. They were classified as conspicuous
when more than 30 were present per 10 high-power fields. 
DNA flow cytometry 
Tumour tissue was minced in cold PBS, filtered through a nylon
mesh (160 µm) and then centrifuged at 400 g for 10 min. The cell
concentration was adjusted to 5–10 ´ 106 ml-1 and 0.5 ml was
added to an equal volume of propidium iodine (PI) detergent solu-
tion (100 µg ml-1 PI, 1% Triton X 100, 1 µg ml-1 RNAse) for
30 min at 4˚C. The suspension was again filtered and the DNA
content of the nuclei was measured by means of an Epics
XL-MCL (Coulter Electronics, FL, USA) using Coulter system II
then multiplus software (Phoenix Technologies, San Diego, USA)
for data acquisition and analysis. All tumour samples were run in
duplicate, together with nuclei from normal colonic mucosa of the
same patient, and with cryopreserved peripheral blood mono-
nuclear cells. Adenocarcinomas with a single G0/G1 peak were
classified as DNA diploid, while tumours with at least two sepa-
rate peaks were considered aneuploid (Hiddemann et al, 1984).
The degree of DNA aneuploidy was expressed as the DNA index
(DI), which represents the ratio of the modal channel position of
the G0/G1 peak of the aneuploid cell population to the diploid
reference cells. Tumours with DI between 0.09 and 1.1 were con-
sidered near-diploid. In all analysis, the coefficient of variation
(CV) of the diploid G0/G1 peaks of tumours as well as normal
samples was less than 5%. 
Microsatellite analysis 
For preparation of DNA, the frozen tissue was macerated in 500 µl
of ice-cold lysis buffer (10 mM Tris-HCl, 1 mM ethylenediamine
tetra-acetic acid (EDTA), 100 mM NaCl, 1% sodium dodecyl
sulphate (SDS), 500 µg ml-1  proteinase K), using a sterile
Eppendorf homogenizer. Following incubation overnight with
shaking at 50˚C, DNA was extracted with phenol/chloroform, and
precipitated with ethanol. 
In all reactions, DNA was amplified in a 10 µl volume contain-
ing 100 ng of DNA, 200 µM dNTPs, 1.5 mM MgCl2, 0.27 µM of
each primer, 0.25 U Tth polymerase in a buffer of 16.6 mM
(NH4)2SO4, 0.45% Triton X 100, 0.2 mg ml-1 gelatine, 67 mM
Tris-HCl, pH 8.8 (Biotech International Ltd, Western Australia).
The reactions were incubated at 95˚C for 5 min, followed by 35
cycles of 95˚C, 57˚C and 72˚C for 1 min each. The primers used in
this study were Bat25, Bat26, D5S346, D2S123 and DI7S250
(Boland et al, 1998). Products were run on an ABI 377 sequencer
(Foster City, California, USA) and analysed using Genescan and
Genotyper software. 
Microsatellite instability (MSI) was defined as either a marked
alteration in repeat length or as a new discrete band above or
below the expected allele. A single observer (RW) performed the
analysis of MSI, and equivocal samples were then re-evaluated
by a second observer (IT). The results were reported without
knowledge of pathological or immunohistochemical status. A
tumour sample was considered to show microsatellite instability
(MSI) if two or more of the markers demonstrated instability. In all
other cases, the tumour was classified as microsatellite stable (MSS). 
Analysis of somatic changes in p53 and K-ras genes 
Mutations at the first and second bases of codon 12 of the K-ras
gene were detected using REMS-PCR as previously described
(Ward et al, 1998). For the identification of accumulation of p53
within tumour cells, paraffin sections of tumour tissue were
subjected to immunohistochemical analysis of p53 as previously
described (Ward et al, 1997), using the mouse anti-human p53
antibody DO7 (DAKO, High Wycombe, UK). Tumour was
considered to show accumulation of p53 protein when more than
20% of tumour cells showed nuclear staining of moderate to high
intensity, in the absence of staining in the stromal cells and normal
epithelium. 
Statistical analysis 
Survival was measured from the date of resection of colorectal
cancer until death or until the cansor date of 1 March 2000. Time
to recurrence was the period from resection to medical documenta-
tion of tumour recurrence. Survival and time to recurrence were
censored at time of death for patients dying of causes other than
colorectal cancer. Survival curves were prepared according to the
method of Kaplan and Meier, and univariate survival distributions
were compared by the log-rank test. Categorical variables were
compared using the Chi-square test or the Fisher’s exact test as
appropriate. A probability value of less than 0.05 was considered
significant. All data was analysed using the SPSS statistical soft-
ware V9.0 (SPSS Inc, Chicago, IL, USA). 
RESULTS 
A total of 46 fresh tumour specimens were assayed from 27 males
and 16 females (ages 54–94, mean 70 ± 9.5 years). Eight of these
Table 1 Clinical characteristics of diploid microsatellite stable, aneuploid
and diploid microsatellite-unstable tumours. Probability was calculated using
Pearson chi-squared 
Diploid MSS Diploid MSI Aneuploid Probability 
Age 
Mean 68.6 78.2 69.3 P = 0.07 
95% CI 63.5–73.8 67.7–88.7 65.8–72.9 
Sex 
Female 5 6* 6 P = 0.01 
Male 9 1* 19* 
Tumour stage 
I3 2 3 P = 0.09 
II 3 4 9 
III 3 1 11 
IV 5 0 2 
Total (%) 14 (30) 7 (15) 25 (54) 
*Factors contributing to a significant correlation, MSS = microsatellite stable,
MSI = microsatellite instability, I–IV represent AJCC/UICC tumour stages 234 NJ Hawkins et al
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tumours were TNM stage I, while 16 were stage II, 15 were stage
III and seven were stage IV. 21 tumours (45%) were diploid, and
seven of these tumours also demonstrated microsatellite instability
(Table 1). Since all the aneuploid cancers were microsatellite-
stable, the tumours were classified into the following groups;
aneuploid (25 of 46, 54%), diploid MSS (14 of 46, 30%) and
diploid MSI (7 of 46, 15%) (Table 1). No difference was found in
the S-phase fraction among the different groups (diploid MSS =
20.7 ± 24.3, aneuploid = 19.9 ± 10.1, diploid MSI = 10.5 ± 8.8). 
There were a number of significant differences in the clinico-
pathological characteristics of the three groups of tumours (Tables
1 and 2). The diploid MSI tumours were significantly more likely
to occur in women, while aneuploid tumours were more likely to
arise in men. Diploid MSI tumours were more likely to be right-
sided tumours, and to harbour increased numbers of intraepithelial
lymphocytes, while there were more left-sided lesions in the aneu-
ploid group. However, the diploid MSS group showed no associa-
tion with sex, tumour sidedness, or the extent of lymphocytic
infiltration within the tumour. 
K-ras mutations at codon 12 were detected in 13 of the 44
tumours analysed (30%), and were less frequent in diploid MSI
tumours (0%) than in stable tumours (54%). Immunohisto-
chemical evidence of p53 accumulation was observed in 17 of 46
tumours (37%), and was much less common in diploid MSI
cancers (0%) than in either diploid MSS (55%) or aneuploid
tumours (92%). In both cases, these differences did not reach
statistical significance (Table 2). 
The presence of metastatic disease at the time of diagnosis was
significantly more common in individuals with diploid MSS
tumours (5 of 14, 35%) than in those with aneuploid (2 of 25, 8%)
or diploid MSI tumours (0 of 7) (P = 0.03). However, there was no
significant correlation between the T or N stage of the tumour and
ploidy/microsatellite status. Comparison of the TNM stage of the
diploid MSS group with the other tumours (aneuploid and diploid
MSI groups combined) further demonstrated the association of the
former with Stage IV disease at presentation (P = 0.01). 
The overall survival curves for patients with all-stage cancers
according to ploidy/microsatellite status are shown in Figure 1.
Despite the fact that individuals with diploid MSS tumours were
more likely to have metastatic disease at the time of diagnosis,
there was no difference in outcome between this group and indi-
viduals with aneuploid tumours, either in terms of overall survival
or time to recurrence. In contrast, the diploid MSI group showed a
trend towards improved overall survival in comparison to the other
groups, and in fact, only one of the seven individuals with a
diploid MSI tumour developed recurrent disease. However, this
difference did not reach statistical significance. The sites of
recurrence did not show any differences between the three
ploidy/microsatellite groups. 
DISCUSSION 
Over many years, a large number of studies have examined the
relationship between nuclear DNA content and clinicopathological
variables in colorectal carcinoma. A number of these studies have
suggested that those tumours with diploid DNA content have a
distinctive morphological appearance and a less aggressive clinical
behaviour (Ruschoff et al, 1997; Forster et al, 1998; Lanza et al,
1998, 1999), yet many other studies have presented contrary
results (Cohn et al, 1997; Tonouchi et al, 1998). Such discrepan-
cies have largely been attributed to methodological variations
related to the type of tissue used and the manner of its collection
(Bauer et al, 1993). 
In this study we have demonstrated that colorectal cancer can be
classified into three distinct groups on the basis of the microsatel-
lite and DNA ploidy status (aneuploid, diploid MSS and diploid
MSI). Many of the observations made in this study regarding the
frequency, phenotype and prognosis of microsatellite-unstable
tumours are in concordance with previously published studies
(Kim et al, 1994; Jass et al, 1998; Halling et al, 1999). These MSI
tumours are more frequent in the right colon and intraepithelial
Table 2 Pathological and genetic characteristics of sporadic colorectal
cancers, based on ploidy and microsatellite analysis 
Tumour  Diploid MSS Aneuploid Diploid MSI Probability 
characteristics
Tumour site 
Right 5 5* 6* P = 0.01 
Left 9 20* 1* 
Intraepithelial ymphocytes
l Increased 2 3 4* P = 0.02 
Normal 12 22 3* 
Tumour differentiation 
Poor 1 2 0 P = 0.75 
Moderate 13 23 7
Mucinous phenotype 
Yes 3 5 2 P = 0.88 
No 11 20 5 
Tumour margins 
Circumscribed 8 18 7 P = 0.12 
Infiltrative 6 7 0
K-ras status (codon 12) 
Mutant 3 10 0 P = 0.16 
Wild-type 11 13 7
p53 protein amount (IHC) 
Increased 5 12 0 P = 0.06 
Normal 9 13 7 
Probability was calculated using Pearson chi-squared. aFactors contributing
to a significant correlation, MSS = microsatellite-stable, MSI = microsatellite
instability, IHC = immunohistochemistry 
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Figure 1 Overall survival plotted according to ploidy/microsatellite status.
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and peritumoural lymphocytic infiltration was often prominent.
Like others, we have found that MSI tumours are more common in
women, that there is a strong correlation between MSI and the
absence of p53 mutations as determined by immunostaining, and
that individuals with such tumours may have an improved clinical
outcome (Fujiwara et al, 1998; Elsaleh et al, 2000). 
Clearly, many of the diploid tumours examined in previous
studies contain a high percentage of these diploid MSI tumours.
Yet they also contain a distinct subgroup of tumours that are both
diploid and microsatellite-stable. These diploid MSS tumours
share few of the distinctive clinicopathological features of the
diploid MSI group, and on this basis clearly represent a distinct
class of colorectal carcinoma. It is apparent that diploid MSS
tumours are equally likely to occur in males as females and that
they originate throughout the colon. 
However, the most striking difference between diploid MSS and
diploid MSI tumours relates to their pattern of invasion and
clinical behaviour. While all diploid MSI tumours demonstrate a
circumscribed growth pattern, nearly half of the diploid MSS
tumours display an infiltrative growth pattern. Likewise, over one
third of individuals with diploid MSS tumours have metastases
present at the time of diagnosis whereas distant spread is not seen
in any of the diploid MSI tumours, and in only 8% of the aneu-
ploid tumours. These observations, together with the survival data,
provide strong support for the argument that diploid MSS tumours
represent an aggressive subset of colorectal carcinomas.
Furthermore, this data suggests a plausible explanation for the
longstanding confusion in the literature regarding the prognostic
significance of aneuploidy, for in all studies to date, the grouping
of diploid tumours includes two biologically distinct tumour types,
with markedly different outcomes. 
It seems paradoxical that tumours with neither chromosomal or
microsatellite instability display apparently early progression,
with an infiltrative phenotype and widespread dissemination at the
time of presentation. One possible explanation may come from the
fact that, by definition, all carcinomas develop an invasive pheno-
type in their progression from adenomas. It is possible that the
unique genetic stability of MSS diploid tumours makes them
better able to maintain an invasive phenotype than either aneu-
ploid or diploid MSI tumours. 
As well as allowing maintenance of a particular phenotype, the
unique genetic stability of diploid MSS tumours could also be
predicted to make those tumours more susceptible to changes in
their environment. In this regard, it is interesting to note that there
are very few established colorectal carcinoma cell lines which are
both diploid and microsatellite-stable (Eshleman et al, 1998).
Furthermore, Wylie and colleagues recently noted that it was not
possible to establish tumour xenografts in nude mice using MSI-
stable, low chromosomal instability tumours (Georgiades et al,
1999). These observations support the hypothesis that genetic
stability lessens the ability of these tumour cells to develop the
biochemical machinery requisite for growth in an altered environ-
ment, either in vitro or in vivo. 
This hypothesis may have considerable importance in terms of
research based on cell culture models of human cancer. For not
only will their be a total absence of diploid MSS cells in any of
these studies, but it is possible that these cells would represent a
far more relevant source for the examination of the biology of
invasion, at least as it pertains to colorectal cancer. 
Of more direct clinical relevance, an inability to respond to
adverse environmental stressors has clear implications for the
success of chemotherapy in these tumours. It has recently been
shown that MSI tumours show a good response to chemotherapy
(Elsaleh et al, 2000), yet in theory it is possible that diploid MSS
tumour cells may be more susceptible to chemotherapeutic agents,
since resistant clones would be less likely to emerge. We can
provide only limited data on the behaviour of these tumours, by
noting that palliative chemotherapy was administered to all five
individuals who presented with stage IV diploid MSS disease and
three showed partial responses to treatment. While this is a much
higher rate of response than would be expected of colorectal carci-
noma in general, the validation of these observations would
require a more extensive study. 
The results of this study support and extend the observations of
Georgiades and colleagues regarding the presence of a distinct
subset of colorectal carcinoma with a uniquely stable genotype,
and highlight the need for further analysis of this group, particu-
larly in terms of their biological behaviour and possible altered
responsiveness to chemotherapy. 
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